0

Shares Of Orexigen Soar 54% After It announces Improved Safety Results For Weight-loss Drug

Shares of Orexigen Therapeuetics (OREX) are up about 54% after the company reported that its Weight-loss Drug Contrave did not only achieve excellent safety results but also saw improvements in other areas. Such other improvements are that when patients took… Continue Reading

0

Celldex Receives Breakthrough Status For Brain Cancer Drug Rindopepimut

Shares of Celldex Therapeutics (CLDX) were up as much as 16% after the company had announced that it had received breakthrough therapy designation for its cancer drug Rindopepimut. Rindopepimut is a drug that is used to treat patients with Glioblastoma… Continue Reading

0

OncoSec Medical and Heat Biologics Collaborate On Immunotherapy Platforms

OncoSec Medical (ONCS) and Heat Biologics (HBTX) both announced today that they will collaborate on clinical trials that will evaluate each company’s platform in a combination study. Both these biotechnology companies utilize a form of technology that uses immunotherapy platforms.… Continue Reading

0

Shares of Oncolytics Surge 36% After The Company Announced Orphan Drug Status For Its Pancreatic Cancer Drug

Shares of Oncolytics Biotech (ONCY) surged 36% after the company had announced that the FDA has granted Orphan Drug Status for its pancreatic cancer drug REYOLYSIN. Oncolytics is a biotechnology company that focuses on using an environmental virus  to combat… Continue Reading

0

Regulus Therapeutics Announces Final Phase 1 Results For Hepatitis C Study Using RG-101

On February 9th, 2015 Shares of Regulus Therapeutics (RGLS) were down 7% despite reporting good final results from the phase 1 study treating patients with Hepatitis C using their injection drug RG-101. Regulus Therapeutics is a biotechnology company focused on… Continue Reading

0

Achillion Pharma Reports 6-week Treatment Cure In Hepatitis C Using Combo Drug Mix

Shares of Achillion Pharmaceuticals (ACHN) gained about 7% in today’s market session after the company reported that combining its Hepatitis C treatment ACH-3102 together with Gilead Sciences (GILD) Hepatitis C treatment Sofosbuvir achieved a 100% cure rate for patients. Achillion… Continue Reading

0

Pfizer Takes Charge And Buys Hospira For $15.2 Billion

Pfizer (PFE) today announced that it has acquired specialty generic drug maker Hospira Inc (HSP) for $15.2 billion, or $90 per share. Hospira has a specialty in injectable type drugs but Pfizer is buying it to expand its global product… Continue Reading

0

Advaxis Is A Biotechnology Company That Should Be Avoided For Now

Shares of Advaxis (ADXS)  hit a 52-week high of 13.74 this year after many press releases of initiating trials. However, management seems to have overstated the efficacy of the company’s drug compound that uses the LLO molecule for immunotherapy purposes.… Continue Reading

0

FDA Removes Partial Clinical Hold For Esperion’s Drug for Bad Cholesterol

Esperion Therapeutics (ESPR) surged as high as 20% in today’s trading session after the company announced that it had received notice from the FDA that the partial clinical hold had been removed for their drug candidate ECT-1002. The removal of… Continue Reading

0

Shares Of Biogen Jump 7% After Hours on Increased Sales Of Multiple Sclerosis Drug

Biogen Idec (BIIB) is a biotechnology company that has a focus on treatments for Multiple Sclerosis and Hemophilia. Shares of Biogen are up 7% after hours after the company reported positive earnings beating out analysts expectations. Biogen’s net income in… Continue Reading